Razi Cov Pars

Razi Cov Pars
Vaccine description
Vaccine typeProtein subunit
Clinical data
Routes of
Intramuscular, Intranasal
Legal status
Legal status

Razi Cov Pars (Persian: رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute.[1][2][3]

It's the second Iranian COVID-19 vaccine reaching human trials[1] and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine.[4][5] It received emergency use authorization in Iran on 31 October 2021.[6][7]

Medical uses

It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray).[3]


Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein.[2]


It's planned to produce one million doses of the vaccine each month as of September 2021.[4]

As of 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health.[8]


Clinical trials

Clinical trials of Razi Cov Pars
PhaseRegistration numberStartNumber of participantsAge of participantsRef
IIRCT20201214049709N121 January 202113330 (5 µg/200µL)

30 (10 µg/200µL)

30 (20 µg/200µL)

30 (placebo)

13 (sentinel)

18-50 years[2]
IIIRCT20201214049709N213 April 202150018-70 years[3]
IIIIRCT20201214049709N329 August 202141,12820,5640 (placebo)

20,564 (Sinopharm BIBP vaccine)

18+ years[5]


Raz Cov Pars received emergency use authorization in Iran on 31 October 2021.[6][7]

See also


  1. ^ a b Mehdi, Syed Zafar (7 February 2021). "Iran unveils second homegrown COVID-19 vaccine". Anadolu Agency. Retrieved 22 April 2021.
  2. ^ a b c "Phase I, Safety and Immunogenicity of Razi SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars), in healthy adults aged 18-55 years; parallel 4 arms design (adjuvant only and three vaccine doses of 5, 10, and 20 µg/200µl); a Randomised, double blind, clinical trial". irct.ir. Iranian Registry of Clinical Trials. Retrieved 21 March 2021.{{cite web}}: CS1 maint: url-status (link)
  3. ^ a b c "Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18-70 years; a Randomised, double blind, parallel 2 arms clinical trial". Iranian Registry of Clinical Trials. Retrieved 22 April 2021.{{cite web}}: CS1 maint: url-status (link)
  4. ^ a b "COVID-19 vaccine Razi Cov Pars starts third clinical trial phase". Tehran Times. 27 August 2021. Retrieved 30 August 2021.
  5. ^ a b "IRCT | Comparison of the safety and efficacy of Razi SARS-CoV-2 recombinant Spike protein (Razi Cov Pars) and Sinopharm vaccines in adults aged 18 and over, a phase III randomised, double blind, non-inferiority clinical trial". en.irct.ir. Retrieved 30 August 2021.
  6. ^ a b "مجوز مصرف اضطراری داوطلبانه واکسن کووپارس صبح امروز صادر شد". ایسنا (in Persian). 31 October 2021. Retrieved 27 November 2021.
  7. ^ a b "Two homegrown vaccines receive emergency use license". Tehran Times. 1 November 2021. Retrieved 27 November 2021.
  8. ^ "۵ میلیون دز واکسن رازی به وزارت بهداشت تحویل داده شد". ایسنا (in Persian). 25 November 2021. Retrieved 27 November 2021.

Media files used on this page

Coronavirus. SARS-CoV-2.png
Author/Creator: Alexey Solodovnikov (Idea, Producer, CG, Editor), Valeria Arkhipova (Scientific Сonsultant), Licence: CC BY-SA 4.0
Scientifically accurate atomic model of the external structure of the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), a strain (genetic variant) of the coronavirus that caused Coronavirus disease (COVID-19), first identified in Wuhan, China, during December 2019

Each separate locus (amorphous blob) is an atom of:

  cobalt: membrane
  crimson: E protein
  green: M protein
  orange: glucose (glycan)
  turquoise : S (spike) glycoprotein
SARS-CoV-2 (Wikimedia colors).svg
Author/Creator: Geraki, Licence: CC BY-SA 4.0
SARS-CoV-2 logo in Wikimedia colors
Scholia logo.svg
Author/Creator: Lars Willighagen, Licence: CC BY-SA 4.0
SVG remake of proposal for Scholia logo (File:Scholia logo.png by User:Theklan).
WHO Rod.svg
The rod of Asclepius as depicted in the WHO logo.
Author/Creator: User:FoeNyx © 2004 (artistic illustration), Licence: CC-BY-SA-3.0
VIH - HIV / SIDA - AIDS viruses.
SARS-CoV-2 (CDC-23312).png
This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by the 2019 Novel Coronavirus (2019-nCoV). Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding the virion, when viewed electron microscopically. This virus was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China.
Syringe with Green Fluid.jpg
Author/Creator: Andres Rueda, Licence: CC BY 2.0
The following is the author's description of the photograph quoted directly from the photograph's Flickr page.
"Just wanted to test something with my ink refiller syringe. Filled with a oral-b mouthwash to give the greenish-blueish Max Payne valkyr effect. "